Filing Flows › Comparisons › TCRX vs DYAI
TScan Therapeutics vs Dyadic International: TCRX and DYAI compared
TScan Therapeutics is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $961K for Dyadic International (Q2 2026). Dyadic International is growing faster (-0.6% against -66% a year earlier).
Where the money goes: TCRX and DYAI
TScan Therapeutics (TCRX) · Q2 2026
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
Dyadic International (DYAI) · Q2 2026
Dyadic International, Q2 2026: revenue $961K (-0.6% year over year), operating margin -213.7%, net loss $2.1M, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
| TScan Therapeutics (TCRX) | Dyadic International (DYAI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.1M | $961K |
| Revenue growth, Y/Y | -66% | -0.6% |
| Operating margin | n/m | -213.7% |
| Net earnings | −$30.4M | −$2.1M |
| Net margin | — | -221.0% |
| Operating cash flow | −$27.5M | −$1.8M |
Where the revenue comes from
Dyadic International
- Grant: $837K (87%)
- Research and Development: $124K (13%)
Questions
Which is bigger, TScan Therapeutics or Dyadic International?
TScan Therapeutics is the larger company: $1.1M of revenue in its latest quarter (Q2 2026) against $961K for Dyadic International (Q2 2026).
Is TScan Therapeutics or Dyadic International growing faster?
Dyadic International is growing faster (-0.6% against -66% a year earlier).
More: TScan Therapeutics earnings · how TScan Therapeutics makes money · Dyadic International earnings · how Dyadic International makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.